Exact Sciences

Exact Sciences schedules second quarter 2021 earnings call

Retrieved on: 
Thursday, July 8, 2021

A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter answers to give people the clarity to take life-changing action, earlier.

Key Points: 
  • A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter answers to give people the clarity to take life-changing action, earlier.
  • Building on the success of Cologuard and Oncotype tests, Exact Sciences is investing in its product pipeline to support patients throughout their cancer diagnosis and treatment.
  • Exact Sciences unites visionary collaborators to help advance the fight against cancer.
  • For more information, please visit the company's website at www.exactsciences.com , follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.

Liquid Biopsy for Cancer Diagnostics Competitive Landscape and Pipeline Analysis Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021

Grail is developing multi-cancer early detection liquid biopsy test or blood test which can detect up to 50 types of cancer and is committed to is committed to develop a deep understanding of cancer biology.

Key Points: 
  • Grail is developing multi-cancer early detection liquid biopsy test or blood test which can detect up to 50 types of cancer and is committed to is committed to develop a deep understanding of cancer biology.
  • GRAIL is poised to detect cancer early by combining high-intensity sequencing of unprecedented breadth and depth with the techniques of modern data science.
  • DNA methylation based liquid biopsy test: Exact Sciences
    Exact's DNA methylation based liquid biopsy test detects 80% of hepatocellular carcinoma (HCC) cases across all stages and 71% of early stage cases.
  • Liquid Biopsy for Cancer Diagnostics: Commercialization Activity
    This segment of the report provides a detailed list of any commercial activity in the field of liquid biopsy products ranging from collaboration, mergers and acquisition, recent breakthrough among others.

Genetic Technologies’ COVID-19 Risk Test Now Available in US through Partnership with Infinity BiologiX

Retrieved on: 
Tuesday, June 1, 2021

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is an Australian based diversified molecular diagnostics company.

Key Points: 
  • Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is an Australian based diversified molecular diagnostics company.
  • The companys lead products, GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer, are clinically validated risk assessment tests and are first in class.
  • Genetic Technologies is developing a pipeline of risk assessment products based on a world leading technology platform created over the past 10 years.
  • Infinity BiologiX (IBX) is a market-disrupting central laboratory supporting academia, government, and industry.

Exact Sciences to participate in June investor conferences

Retrieved on: 
Monday, May 24, 2021

MADISON, Wis., May 24, 2021 /PRNewswire/ --Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following virtual conferences and invited investors to participate by webcast.

Key Points: 
  • MADISON, Wis., May 24, 2021 /PRNewswire/ --Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following virtual conferences and invited investors to participate by webcast.
  • A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter answers to give people the clarity to take life-changing action, earlier.
  • Building on the success of Cologuard and Oncotype tests, Exact Sciences is investing in its product pipeline to support patients throughout their cancer diagnosis and treatment.
  • For more information, please visit the company's website at www.exactsciences.com , follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.

Modeling Data Showed Cologuard® Was Superior to Fecal Immunochemical Test (FIT) on Cost Effectiveness and Colorectal Cancer Incidence and Mortality

Retrieved on: 
Friday, May 21, 2021

Cologuard is included in the American Cancer Society's (2018) colorectal cancer screening guidelines and the recommendations of the U.S. Preventive Services Task Force (2016) and National Comprehensive Cancer Network (2016).

Key Points: 
  • Cologuard is included in the American Cancer Society's (2018) colorectal cancer screening guidelines and the recommendations of the U.S. Preventive Services Task Force (2016) and National Comprehensive Cancer Network (2016).
  • Do not use Cologuard if you have had precancer, have inflammatory bowel disease and certain hereditary syndromes, or have a personal or family history of colorectal cancer.
  • Cologuard performance in repeat testing has not been evaluated.\nThe Cologuard test result should be interpreted with caution.
  • Estimating the screening-eligible population size, aged 45 to 74, at average risk to develop colorectal cancer in the United States.

The Access to Comprehensive Genomic Profiling Coalition Adds New Member

Retrieved on: 
Thursday, May 20, 2021

b'WASHINGTON, May 20, 2021 /PRNewswire/ --The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of Mayo Clinic Laboratories to its coalition of diagnostics companies and laboratory service providers to advocate for appropriate broad U.S. health insurance coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer.\n"On behalf of ACGP, we welcome Mayo Clinic Laboratories to the coalition working to advocate for access to comprehensive genomic profiling (CGP) for patients living with advanced cancer," said Jim Almas, MD, vice president and national medical director of clinical effectiveness at Labcorp, and chairman of ACGP.

Key Points: 
  • b'WASHINGTON, May 20, 2021 /PRNewswire/ --The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of Mayo Clinic Laboratories to its coalition of diagnostics companies and laboratory service providers to advocate for appropriate broad U.S. health insurance coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer.\n"On behalf of ACGP, we welcome Mayo Clinic Laboratories to the coalition working to advocate for access to comprehensive genomic profiling (CGP) for patients living with advanced cancer," said Jim Almas, MD, vice president and national medical director of clinical effectiveness at Labcorp, and chairman of ACGP.
  • "The addition of Mayo Clinic Laboratories, a recognized global reference laboratory that supports patient care and access to specialized testing, is further evidence of growing stakeholder interest in improving access to CGP.
  • "\nCGP testing performed soon after a diagnosis of advanced cancer better informs medical management, including treatment decisions and patient care, which can improve clinical outcomes.
  • If you are interested in learning more about becoming a member, please contact us here .\nAccess to Comprehensive Genomic Profiling (ACGP) is a collaborative coalition of leading molecular diagnostics companies and laboratories that aims to raise awareness about comprehensive genomic profiling (CGP) for advanced cancer patients.\n'

Worldwide Breast Cancer Liquid Biopsy Industry to 2027 - Increase in Demand for Safe and Non-Invasive Procedures are Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 20, 2021

Breast cancer liquid biopsy is a simple & precise alternative to surgical biopsy procedures, which allows physicians and surgeons to detect & treat breast cancer at an early stage and obtain tumor information through blood samples.

Key Points: 
  • Breast cancer liquid biopsy is a simple & precise alternative to surgical biopsy procedures, which allows physicians and surgeons to detect & treat breast cancer at an early stage and obtain tumor information through blood samples.
  • Breast cancer liquid biopsy is particularly significant as it helps physicians to understand molecular changes and dynamics of breast cancer.
  • Moreover, breast cancer recurrence is expected to be understood through well-timed breast cancer liquid biopsy techniques.\nRise in prevalence of breast cancer, increase in preference for noninvasive procedures, technological advancements in breast cancer liquid biopsy instruments, advantages of over solid tumor biopsy, and increase in patient awareness toward minimally invasive breast cancer liquid biopsy procedures are the key factors that fuel growth of the breast cancer liquid biopsy market.
  • However, limitations associated with liquid biopsy testing and lack of access and awareness regarding breast cancer liquid biopsy in underdeveloped countries are expected to hinder the growth of the market.\nThe global breast cancer liquid biopsy market is segmented on the basis of product & service, circulating biomarker, application, and region.

Exact Sciences Strengthens Evidence Supporting Cologuard® and Oncotype DX® Tests and Deep Oncology Pipeline with Multiple Data Presentations at ASCO 2021

Retrieved on: 
Thursday, May 20, 2021

"Exact Sciences is changing the way we detect and treat cancer.

Key Points: 
  • "Exact Sciences is changing the way we detect and treat cancer.
  • Building on the success of Cologuard and Oncotype tests, Exact Sciences is investing in its product pipeline to support patients throughout their cancer diagnosis and treatment.
  • For more information, please visit the company\'s website at www.exactsciences.com , follow Exact Sciences on Twitter @ExactSciences , or find Exact Sciences on Facebook.\nNOTE: Oncotype, Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX Breast DCIS Score, Oncotype DX Genomic Prostate Score, Oncotype MAP Pan-Cancer Tissue, and Oncotype DX AR-V7 Nucleus Detect are trademarks or registered trademarks of Genomic Health, Inc.
  • Exact Sciences and Cologuard are trademarks or registered trademarks of Exact Sciences Corporation.

Exact Sciences Strengthens Evidence Supporting Cologuard® and Oncotype DX® Tests and Deep Oncology Pipeline with Multiple Data Presentations at ASCO 2021

Retrieved on: 
Wednesday, May 19, 2021

"Exact Sciences is changing the way we detect and treat cancer.

Key Points: 
  • "Exact Sciences is changing the way we detect and treat cancer.
  • Building on the success of Cologuard and Oncotype tests, Exact Sciences is investing in its product pipeline to support patients throughout their cancer diagnosis and treatment.
  • For more information, please visit the company\'s website at www.exactsciences.com , follow Exact Sciences on Twitter @ExactSciences , or find Exact Sciences on Facebook.\nNOTE: Oncotype, Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX Breast DCIS Score, Oncotype DX Genomic Prostate Score, Oncotype MAP Pan-Cancer Tissue, and Oncotype DX AR-V7 Nucleus Detect are trademarks or registered trademarks of Genomic Health, Inc.
  • Exact Sciences and Cologuard are trademarks or registered trademarks of Exact Sciences Corporation.

Exact Sciences Announces First Quarter 2021 Results

Retrieved on: 
Tuesday, May 4, 2021

b'MADISON, Wis., May 4, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $402.1 million for the first quarter ended March31, 2021, compared to $347.8 million for the same period of 2020.\n"The first quarter demonstrated Exact Sciences is well-positioned for growth today and into the future," said Kevin Conroy, Chairman and CEO.

Key Points: 
  • b'MADISON, Wis., May 4, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $402.1 million for the first quarter ended March31, 2021, compared to $347.8 million for the same period of 2020.\n"The first quarter demonstrated Exact Sciences is well-positioned for growth today and into the future," said Kevin Conroy, Chairman and CEO.
  • ET to discuss first quarter 2021 results.
  • The Oncotype DX AR-V7 Nucleus Detect test is performed by Epic Sciences at its centralized, CLIA-certified laboratory in San Diego and offered exclusively by Exact Sciences.
  • For more information, please visit the company\'s website at www.exactsciences.com , follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.\nThis news release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future.